CATALYST PHARMACEUTICALS, INC.

Form 8-K November 09, 2016

### **UNITED STATES**

### SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

### FORM 8-K

### **CURRENT REPORT**

### **PURSUANT TO SECTION 13 OR 15(d)**

### OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of Earliest Event Reported): November 9, 2016

## CATALYST PHARMACEUTICALS, INC.

(Exact Name Of Registrant As Specified In Its Charter)

Delaware (State or other jurisdiction

**001-33057** (Commission

**76-0837053** (I.R.S. Employer

of incorporation)

File Number)

**Identification No.)** 

355 Alhambra Circle

33134

# Edgar Filing: CATALYST PHARMACEUTICALS, INC. - Form 8-K Suite 1250

Coral Gables, Florida
(Address of principal executive offices)

Registrant s telephone number, including area code: (305) 529-2522

### Not Applicable

### Former Name or Former address, if changed since last report

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

### **Item 8.01 Other Events**

On November 9, 2016, the Company issued a press release announcing its results of operations for the three and nine months ended September 30, 2016. A copy of the press release is attached hereto as Exhibit 99.1.

## Item 9.01 Financial Statements and Exhibits.

- (d) Exhibits
- 99.1 Press release issued by the Company on November 9, 2016.

2

### **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

# **Catalyst Pharmaceuticals, Inc.**

By: /s/ Alicia Grande

Alicia Grande

Vice President, Treasurer and CFO

Dated: November 9, 2016